fetching data ...

AB0999 (2020)
HALLMARK CLINICAL FEATURES of JUVENILE PSORIATIC ARTHRITIS (JPSA)
K. Aleksanyan1, S. Chebysheva1, A. Meleshkina1, E. Popova1, E. Zholobova1
1I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation

Background: JPsA is presented in 4 to 9% children with juvenile arthritis [1,2]. According to ILAR criteria, patients with uveitis, HLA-B27-positivity, and other exclusion criteria cannot be included in the JPsA category. Therefore, in pediatric rheumatological practice, the Vancouver criteria are more often used [3].


Objectives: to identify clinical features of psoriatic arthritis in children.


Methods: a single center, prospective and retrospective, continuous clinical trial for the period from 1989 to 2019 was conducted.


Results: We observed 83 patients with JPsA aged from 4 months to 17 years. Fifty-nine (71%) patients had definite JPsA and 24 (29%) had probable JPsA, according to the Vancouver criteria. The clinical and demographic characteristics are presented in Table 1 .

The clinical and demographic characteristics of patients with JPsA (n=83)

Demographic indicators JPsA М ± σ (Ме )
Definite Probable
Number of patients (n) 59 24
Girl/Boy Ratio 1,7:1 2:1
Average age, years 6,6±4 (5) 6,3±2,7 (5)
Duration of the disease, years 3 ±2 (3)
Family history of psoriasis n, (%) First-degree relative with psoriasis 22 (26%)
Second-degree relative with psoriasis 34 (41%)
Potential trigger n, (% ) Infection 22 (27%)
Trauma 12 (14%)
Vaccination 7 (8%)
Insolation 5 (6%)
Stress 3 (4%)
Not identified 34 (41%)

In 17 (29%) children with definite JPsA, skin lesions presented as the first sign of the disease, joint damage in these patients developed after 3.5 ± 2 (2) years. In 28 (48%) patients articular syndrome was observed on the onset with subsequent skin manifestations after 5.3 ± 3 (5) years. Fourteen (23%) children with definite JPsA had simultaneous debut of skin and articular syndromes ( Fig.1 ).

Skin and / or articular syndromes in the onset of the disease in children with definite JPsA

Among 59 patients with definite JPsA, vulgar psoriasis was observed in 45 (76%) patients, guttate psoriasis in 9 (15%), isolated nail psoriasis in 3 (5%), and palmoplantar psoriasis in 2 (4%). Fifteen (28%) patients had a combination of cutaneous psoriasis with damage to the nail plates.

Articular syndrome in the onset of the disease was represented by oligoarticular arthritis in 57 (69%) patients, in 15 (18%) children - symmetric rheumatoid-like arthritis, and in 11 (13%) - spondylitis. The most commonly involved joints at both presentation and during the course of the disease were the knee (41%), ankle (31%), and small joints of the hands (29%). During course of the disease, the articular syndrome transformed with symmetric rheumatoid-like arthritis prevalence ( Fig. 2 ).

Articular syndrome JPsA in the onset and during the disease course (n, %)

In 39 (47%) children, the disease at onset was characterized by high level of ESR – 34±12 (32) mm/h.


Conclusion: In most patients with JPsA, the onset of the disease occurred at the age of 6.6±4 years. Articular syndrome in the onset of the disease was presented as oligoarticular arthritis in 69% children. Overall, transformation to symmetric rheumatoid-like arthritis was the most common. Skin lesions were represented by vulgar psoriasis in 76%, guttate psoriasis in 15%, isolated nail psoriasis in 5%, palmoplantar psoriasis in 4%, and 28% of patients had a combination of cutaneous psoriasis with damage to the nail plates.


REFERENCES:

[1]Beukelman, T., et al. The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. Pediatr Rheumatol Online J. 2017;15(1):30

[2]Horneff G., et al. Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry. Clin. Exp. Rheumatol. 2016; 34(6):1113–1120.

[3]Southwood T.R., et al. Psoriatic arthritis in children. Arthritis Rheum.1989; 32(8):1007-1013.


Disclosure of Interests: Karina Aleksanyan: None declared, Svetlana Chebysheva: None declared, Angelina Meleshkina: None declared, Ekaterina Popova: None declared, Elena Zholobova Grant/research support from: Novartis and Pfizer Inc, Speakers bureau: AbbVie, Novartis, Pfizer Inc and Roche


Citation: Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1788
Session: Paediatric rheumatology (Abstracts Accepted for Publication)